News
PFE
26.36
+2.29%
0.59
The Stock Market Is Historically Pricey: Here's How I'm Positioning My Portfolio for 2025
The Motley Fool · 22h ago
My Top 10 Stocks to Buy for 2025
The Motley Fool · 23h ago
FDA Grants Accelerated Approval To Pfizer's BRAFTOVI Combination For Metastatic Colorectal Cancer
NASDAQ · 1d ago
Pfizer gets FDA accelerated approval for Braftovi
Seeking Alpha · 1d ago
Notable Friday Option Activity: RYTM, PFE, PEP
NASDAQ · 1d ago
Pfizer Gains FDA Approval for Colorectal-Cancer Treatment
Dow Jones · 1d ago
Pfizer announces FDA approval of Braftovi combination
TipRanks · 1d ago
Pfizer: Navigating Revenue Challenges and Opportunities with a Hold Rating
TipRanks · 1d ago
Validea Detailed Fundamental Analysis - PFE
NASDAQ · 1d ago
Impax Global Social Leaders Fund Q3 2024 Commentary
Seeking Alpha · 1d ago
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals
Barchart · 2d ago
After Hours Most Active for Dec 19, 2024 : NVDA, AAPL, TLT, SNAP, F, RIVN, NU, CSCO, GOOG, PFE, NKE, KO
NASDAQ · 2d ago
Sangamo: Pipeline Expansion Via Partnership And Internal ST-503 Development
Seeking Alpha · 2d ago
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
Benzinga · 2d ago
Regeneron reports positive results for two anti-coagulant drugs
Seeking Alpha · 2d ago
Viking Therapeutics: Competition Fears Are Exaggerated
Seeking Alpha · 2d ago
Impax Global Opportunities Fund Q3 2024 Commentary
Seeking Alpha · 2d ago
Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26?
The Motley Fool · 2d ago
Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts
Barchart · 2d ago
What's Next For Pfizer Stock?
NASDAQ · 3d ago
More
Webull provides a variety of real-time PFE stock news. You can receive the latest news about Pfizer through multiple platforms. This information may help you make smarter investment decisions.
About PFE
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.